Investors in Cullinan Therapeutics Inc (Symbol: CGEM) saw new options become available today, for the April 2025 expiration. One of the key data points that goes into the price an option buyer is ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and ...

Cullinan Therapeutics, Inc. (CGEM) on Tuesday reported a loss of $50.7 million in its fourth quarter. On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 77 cents.

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Cullinan Therapeutics Inc (Symbol: CGEM), where a total of 5,055 contracts have traded so ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability ...

CGEM has an interesting “modality‑agnostic” approach that focuses on targets first, then models yield the most promising candidates. This way, CGEM has built a relatively well-diversified oncology and ...

Taiho Oncology Inc. and Cullinan Therapeutics Inc. (NASDAQ:CGEM) shared new data on Sunday from the central nervous system (CNS) involvement cohort of the REZILIENT2 study of zipalertinib for advanced ...

Cullinan Therapeutics is a multifocal biotech with promising programs in precision medicine and immunotherapy, despite recent market sentiment declines. Zipalertinib shows potential in treating exon ...